Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits

Código QR

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits

Abayomi B Ogundele, Guangming Li, Joel J EllisAlcon Research, Ltd., Fort Worth, TX, USAIntroduction: The purpose of this study was to examine and compare the conjunctival irritation (congestion, swelling, and discharge) of topical bimatoprost ophthalmic solution 0.01% and bimatoprost ophthalmic solu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abayomi B Ogundele, Guangming Li, Joel J Ellis
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a68abd52cfdb43ebb358af83881faefc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin J-E, et al.
Publicado: (2011)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
por: Deshpande SS, et al.
Publicado: (2017)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: E Randy Craven, et al.
Publicado: (2010)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell JH, et al.
Publicado: (2014)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Laube T, et al.
Publicado: (2012)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
por: Wirta D, et al.
Publicado: (2011)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
por: Nixon DR, et al.
Publicado: (2012)

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial
por: Crichton AC, et al.
Publicado: (2014)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens A, et al.
Publicado: (2016)

Periorbital muscle atrophy associated with topical bimatoprost therapy
por: Wang PX, et al.
Publicado: (2014)

Si0.97Ge0.03 microelectronic thermoelectric generators with high power and voltage densities
por: Ruchika Dhawan, et al.
Publicado: (2020)

Effect of topical Mitomycin-C (0.01%) in treatment of severe vernal refractory keratoconjunctivitis
por: SMH Emad, et al.
Publicado: (2005)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
por: Hassan Sajjad Rathore, et al.
Publicado: (2021)

Bimatoprost in the treatment of eyelash hypotrichosis
por: Simon K Law
Publicado: (2010)

Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study
por: Sayed KM, et al.
Publicado: (2019)

Evolution of the intrinsic electronic phase separation in La0.6Er0.1Sr0.3MnO3 perovskite
por: Lili Chen, et al.
Publicado: (2016)

Improved electrochemical properties of LiNi0.91Co0.06Mn0.03O2 cathode material via Li-reactive coating with metal phosphates
por: Kyoungmin Min, et al.
Publicado: (2017)

A multicenter Spanish study of atropine 0.01% in childhood myopia progression
por: Inés Pérez-Flores, et al.
Publicado: (2021)

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema
por: Giarmoukakis AK, et al.
Publicado: (2020)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017)

Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
por: Can Cui, et al.
Publicado: (2021)

Optical properties of chalcogenide (As2S1.5Se1.5)0.99:Sn0.01 thin films
por: Iaseniuc, Oxana, et al.
Publicado: (2010)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
por: Shen J, et al.
Publicado: (2018)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
por: Scott D Smid
Publicado: (2009)

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
por: Higashiyama T, et al.
Publicado: (2018)

An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
por: Borchert M, et al.
Publicado: (2016)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017)

Crystal structure and dielectric properties of layered perovskite-like solid solutions Bi3−x Gdx TiTaO9 (x = 0.0, 0.1, 0.2, 0.3) with high Curie temperature
por: S. V. Zubkov
Publicado: (2021)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)